Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 3Phase 2 3Phase 1 3Phase NA 1Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Strabismus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Mucositis 1Lung Neoplasms 1Insulin Resistance 1Infertility, Female 1Infertility 1Hyperphagia 1Hyperglycemia 1Febrile Neutropenia 1Emergence Delirium 1

Interventions

niraparib 4olaparib 2apatinib 2Sevoflurane 2Saline Solution 2Propofol 2Carboplatin 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1palbociclib 1liposomal doxorubicin 1lenvatinib 1gadofosveset trisodium 1fosaprepitant 1ferrous fumarate 1Tranexamic Acid 1Trabectedin 1Sunitinib 1Sodium Chloride 1Pharmacokinetics 1Patient-Specific Modeling 1Pafolacianine 1Paclitaxel 1LY 353381 1Injections 1Indocyanine Green 1Folic Acid 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Ovarian Neoplasms × Injections × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡